Breaking Finance News

Theravance Biopharma Inc (NASDAQ:TBPH) has been downgraded to Underperform in a statement by Robert W. Baird earlier today.

Displaying a price of $37.44, Theravance Biopharma Inc (NASDAQ:TBPH) traded -8.88% lower on the day. With the last stock price up 14.61% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same period. TBPH has recorded a 50-day moving average of $33.14 and a two hundred day average of $25.33. 685,248 shares of TBPH traded, up from an average trading volume of 242,689

Robert W. Baird has downgraded Theravance Biopharma Inc (NASDAQ:TBPH) to Underperform in a statement released on 10/12/2016.

Previously on Tuesday October 04, 2016, Zacks Investment Research released a statement about Theravance Biopharma Inc (NASDAQ:TBPH) increased the target price from $0.00 to $41.00. At the time, this suggested an upside of 0.13%.

Recent Performance Chart

Theravance Biopharma Inc (NASDAQ:TBPH)

Theravance Biopharma Inc has a with a one year low of $12.87 and a one year high of $38.92 The company’s market cap is currently $0.

In addition to Robert W. Baird reporting its stock price target, a total of 1 brokerage has released a ratings update on TBPH. The one year target price is $19.00 with 1 firm rating the stock a strong buy, 0 brokerages rating the stock a buy, 1 broker rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.

About Theravance Biopharma Inc (NASDAQ:TBPH)

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.